Ultra‐Small Nano‐Assemblies as Tumor‐Targeted and Renal Clearable Theranostic Agent for Photodynamic Therapy
Source abstract
Abstract
Abstract It is a challenge to design photosensitizers to balance between the tumor‐targeting enrichment for precise treatment and efficient clearance within a reasonable timescale for reducing side effects. Herein, an ultra‐small nano‐photosensitizer 1a with excellent tumor‐specific accumulation and renal clearance is reported. It is formed from the self‐assembly of compound 1 bearing three triethylene glycol (TEG) arms and two pyridinium groups in water. The positively charged surface with neutral TEG coating enables 1a to efficiently target the tumor, with the signal‐to‐background ratio reaching as high as 11.5 after tail intravenous injection. The ultra‐small size of 1a with an average diameter of 5.6 nm allows its fast clearance through kidney. Self‐assembly also endows 1a with an 18.2‐fold enhancement of reactive oxygygen species generation rate compared to compound 1 in organic solution. Nano‐PS 1a manifests an excellent photodynamic therapy efficacy on tumor‐bearing mouse models. This work provides a promising design strategy of photosensitizers with renal clearable and tumor‐targeting ability.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Radiopharmaceuticals Ministry of Education College of Chemistry Beijing Normal University Beijing 100875 P. R. China
State Key Laboratory of Biochemical Engineering Institute of Process Engineering Chinese Academy of Sciences Beijing 100190 P. R. China
Funding
National Natural Science Foundation of China
References (63)
Show source-provided references
1. 10.1007/s12094-008-0172-210.1007/s12094-008-0172-2 ↗
2. dos Santos A. l. F. · J Cancer Metastasis Treat · 2019 · 5 · 25
3. 10.1021/acs.chemrev.1c0038110.1021/acs.chemrev.1c00381 ↗
4. 10.1002/adhm.20190013210.1002/adhm.201900132 ↗
5. 10.1002/adma.20210079510.1002/adma.202100795 ↗
6. 10.1039/D0CS00173B10.1039/D0CS00173B ↗
7. 10.1016/j.biomaterials.2019.11957810.1016/j.biomaterials.2019.119578 ↗
8. 10.1021/acs.chemmater.1c0117310.1021/acs.chemmater.1c01173 ↗
9. 10.1002/ange.20201247710.1002/ange.202012477 ↗
10. 10.1007/s00280-005-0015-610.1007/s00280-005-0015-6 ↗
11. 10.1039/D0CS01370F10.1039/D0CS01370F ↗
12. 10.1021/jacs.7b1103610.1021/jacs.7b11036 ↗
13. 10.7150/thno.1886110.7150/thno.18861 ↗
14. 10.1002/wnan.159910.1002/wnan.1599 ↗
15. 10.1002/ange.20190325610.1002/ange.201903256 ↗
16. 10.1016/j.jconrel.2020.10.04010.1016/j.jconrel.2020.10.040 ↗
17. 10.1002/adma.20160110110.1002/adma.201601101 ↗
18. 10.1021/acs.chemmater.7b0392410.1021/acs.chemmater.7b03924 ↗
19. 10.1021/acsabm.9b0084310.1021/acsabm.9b00843 ↗
20. 10.1021/jacs.8b0233110.1021/jacs.8b02331 ↗
21. 10.1021/acs.accounts.2c0033510.1021/acs.accounts.2c00335 ↗
22. 10.1039/C7CS00594F10.1039/C7CS00594F ↗
23. 10.1039/c3nr02176a10.1039/c3nr02176a ↗
24. 10.1002/adma.20200422510.1002/adma.202004225 ↗
25. 10.1021/jacs.8b0911710.1021/jacs.8b09117 ↗
26. 10.1021/cr500419810.1021/cr5004198 ↗
27. 10.1002/anie.20140303610.1002/anie.201403036 ↗
28. 10.1023/A:102018650584810.1023/A:1020186505848 ↗
29. 10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
30. 10.1002/adhm.20190122310.1002/adhm.201901223 ↗
31. 10.1038/s41578-018-0038-310.1038/s41578-018-0038-3 ↗
32. 10.1038/s41565-019-0499-610.1038/s41565-019-0499-6 ↗
33. 10.1002/ppsc.20200027010.1002/ppsc.202000270 ↗
34. 10.1016/j.mattod.2013.11.00310.1016/j.mattod.2013.11.003 ↗
35. 10.1002/adma.20190589910.1002/adma.201905899 ↗
36. 10.7150/thno.7280310.7150/thno.72803 ↗
37. 10.1152/ajprenal.2001.280.3.F39610.1152/ajprenal.2001.280.3.F396 ↗
38. 10.1073/pnas.191254911610.1073/pnas.1912549116 ↗
39. 10.1039/D2CC04191J10.1039/D2CC04191J ↗
40. 10.1039/D2SC01469F10.1039/D2SC01469F ↗
41. 10.1039/D0SC01122C10.1039/D0SC01122C ↗
42. 10.7150/thno.3450910.7150/thno.34509 ↗
43. 10.1038/ncomms900310.1038/ncomms9003 ↗
44. 10.1038/nnano.2009.31410.1038/nnano.2009.314 ↗
45. 10.1039/C2CS35216H10.1039/C2CS35216H ↗
46. 10.1021/acsnano.9b1001510.1021/acsnano.9b10015 ↗
47. 10.1039/D0SM02050H10.1039/D0SM02050H ↗
48. 10.1002/agt2.9610.1002/agt2.96 ↗
49. 10.1021/jacs.9b0922010.1021/jacs.9b09220 ↗
50. 10.1002/anie.20180513810.1002/anie.201805138 ↗
51. 10.31635/ccschem.021.20210160010.31635/ccschem.021.202101600 ↗
52. 10.1021/acsmaterialslett.2c0097210.1021/acsmaterialslett.2c00972 ↗
53. 10.1038/s41467-022-30721-w10.1038/s41467-022-30721-w ↗
54. 10.1002/anie.20180760210.1002/anie.201807602 ↗
55. 10.1039/C4CC00746H10.1039/C4CC00746H ↗
56. 10.1021/acsami.8b1509810.1021/acsami.8b15098 ↗
57. 10.1021/acs.accounts.8b0029210.1021/acs.accounts.8b00292 ↗
58. 10.1002/adma.20180210510.1002/adma.201802105 ↗
59. 10.1007/s11307-022-01736-y10.1007/s11307-022-01736-y ↗
60. 10.1002/cncr.3041910.1002/cncr.30419 ↗
61. Jiang J. X. · Am. J. Nucl. Med. Mol. Imaging · 2015 · 5 · 390
62. 10.3171/2018.7.JNS18164210.3171/2018.7.JNS181642 ↗
63. 10.1093/toxsci/kfv11410.1093/toxsci/kfv114 ↗